The inhibition of carbohydrate hydrolyzing enzyme represents a type 2 diabetes mellitus therapy, and cholinesterase inhibition has been applied to treat Alzheimer’s disease (AD). This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.